JP2014505074A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014505074A5 JP2014505074A5 JP2013551327A JP2013551327A JP2014505074A5 JP 2014505074 A5 JP2014505074 A5 JP 2014505074A5 JP 2013551327 A JP2013551327 A JP 2013551327A JP 2013551327 A JP2013551327 A JP 2013551327A JP 2014505074 A5 JP2014505074 A5 JP 2014505074A5
- Authority
- JP
- Japan
- Prior art keywords
- propoxy
- hydroxy
- isopropylamino
- methyl
- phenylpropionate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims description 67
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 65
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 claims description 58
- 150000003839 salts Chemical class 0.000 claims description 58
- 230000036772 blood pressure Effects 0.000 claims description 37
- 208000001871 Tachycardia Diseases 0.000 claims description 25
- 230000006794 tachycardia Effects 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 101150033809 ADRB2 gene Proteins 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- GXLJZLBKWSJXFP-UHFFFAOYSA-N phenyl propanoate;hydrochloride Chemical compound Cl.CCC(=O)OC1=CC=CC=C1 GXLJZLBKWSJXFP-UHFFFAOYSA-N 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- -1 isopropylamino Chemical group 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 claims 2
- VZTMYLWJKCAXMZ-UHFFFAOYSA-N 2-[(2-chloroquinazolin-4-yl)amino]ethanol Chemical compound C1=CC=C2C(NCCO)=NC(Cl)=NC2=C1 VZTMYLWJKCAXMZ-UHFFFAOYSA-N 0.000 description 38
- 229960001015 esmolol hydrochloride Drugs 0.000 description 38
- 229960003745 esmolol Drugs 0.000 description 36
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 36
- 238000000034 method Methods 0.000 description 35
- 208000011580 syndromic disease Diseases 0.000 description 30
- 239000003814 drug Substances 0.000 description 21
- 230000007812 deficiency Effects 0.000 description 12
- 238000002695 general anesthesia Methods 0.000 description 12
- 238000002693 spinal anesthesia Methods 0.000 description 12
- 102220624485 Beta-2 adrenergic receptor_G16R_mutation Human genes 0.000 description 10
- 208000001089 Multiple system atrophy Diseases 0.000 description 10
- 206010031127 Orthostatic hypotension Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 6
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 6
- 108700019265 Aromatic amino acid decarboxylase deficiency Proteins 0.000 description 6
- 206010003591 Ataxia Diseases 0.000 description 6
- 206010008027 Cerebellar atrophy Diseases 0.000 description 6
- 206010016202 Familial Amyloidosis Diseases 0.000 description 6
- 208000035268 Mast Cell Activation disease Diseases 0.000 description 6
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 6
- 208000012583 Menkes disease Diseases 0.000 description 6
- 102000010909 Monoamine Oxidase Human genes 0.000 description 6
- 108010062431 Monoamine oxidase Proteins 0.000 description 6
- 240000007817 Olea europaea Species 0.000 description 6
- 201000011252 Phenylketonuria Diseases 0.000 description 6
- 206010069116 Tetrahydrobiopterin deficiency Diseases 0.000 description 6
- 201000007073 Triple A syndrome Diseases 0.000 description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 6
- 229960002478 aldosterone Drugs 0.000 description 6
- 201000004001 aromatic L-amino acid decarboxylase deficiency Diseases 0.000 description 6
- 230000002567 autonomic effect Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 108700006189 dopamine beta hydroxylase deficiency Proteins 0.000 description 6
- 208000009308 dopamine beta-hydroxylase deficiency Diseases 0.000 description 6
- 210000004115 mitral valve Anatomy 0.000 description 6
- 201000001119 neuropathy Diseases 0.000 description 6
- 230000007823 neuropathy Effects 0.000 description 6
- 208000033808 peripheral neuropathy Diseases 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 208000001953 Hypotension Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 230000003796 beauty Effects 0.000 description 2
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002746 orthostatic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000029865 regulation of blood pressure Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161436992P | 2011-01-27 | 2011-01-27 | |
| US61/436,992 | 2011-01-27 | ||
| PCT/US2012/022696 WO2012103314A1 (en) | 2011-01-27 | 2012-01-26 | Methods of treating tachycardia and/or controlling heart rate while minimizing and/or controlling hypotension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014505074A JP2014505074A (ja) | 2014-02-27 |
| JP2014505074A5 true JP2014505074A5 (enExample) | 2015-03-19 |
Family
ID=45567141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013551327A Withdrawn JP2014505074A (ja) | 2011-01-27 | 2012-01-26 | 血圧低下を最小化しおよび／または制御しながら頻脈を治療しおよび／または心拍数を制御する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8686036B2 (enExample) |
| EP (1) | EP2667867B1 (enExample) |
| JP (1) | JP2014505074A (enExample) |
| KR (1) | KR20140034729A (enExample) |
| CN (1) | CN103338763A (enExample) |
| AU (1) | AU2012211318C1 (enExample) |
| BR (1) | BR112013016701A2 (enExample) |
| CA (1) | CA2825311A1 (enExample) |
| MX (1) | MX2013008713A (enExample) |
| WO (1) | WO2012103314A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012211309B2 (en) | 2011-01-27 | 2014-10-09 | Baxter Healthcare Sa | Use of (S) - esmolol for controlling venous irritation associated with the treatment of a cardiac disorder |
| RU2613564C1 (ru) * | 2015-12-02 | 2017-03-17 | федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Западный государственный медицинский университет имени И.И. Мечникова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СЗГМУ им. И.И. Мечникова Минздрава России) | Способ прогнозирования интраоперационной артериальной гипотензии при проведении анестезии |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0720861B2 (ja) | 1984-04-09 | 1995-03-08 | ザ デュポン マーク ファーマソウテイカル カンパニー | 心臓障害の処置または予防用の医薬組成物および方法 |
| JPS63502585A (ja) * | 1985-12-04 | 1988-09-29 | ザ デュポン メルク ファーマシュウティカル カンパニー | アリルオキシプロパノ−ルアミン類及びアリルエタノ−ルアミン類の合成法 |
| WO1988001614A1 (en) | 1986-09-02 | 1988-03-10 | E.I. Du Pont De Nemours And Company | RESOLUTION OF dl-METHYL 3-[4-(2-HYDROXY-3-ISOPROPYLAMINO)PROPOXY]PHENYLPROPIONATE [(dl-ESMOLOL)] |
| US4857552A (en) | 1988-06-08 | 1989-08-15 | E. I. Du Pont De Nemours And Co. | Stable pharmaceutical composition |
| US5849843A (en) | 1993-11-16 | 1998-12-15 | Baxter International Inc. | Polymeric compositions for medical packaging and devices |
| US5998019A (en) | 1993-11-16 | 1999-12-07 | Baxter International Inc. | Multi-layered polymer structure for medical products |
| US5977409A (en) | 1997-04-15 | 1999-11-02 | University Of Toledo | Method of using α-substituted benzylamine chiral auxiliary synthetic reagents |
| US6310094B1 (en) | 2001-01-12 | 2001-10-30 | Baxter International Inc. | Ready-to-use esmolol solution |
| TWI277414B (en) | 2001-01-12 | 2007-04-01 | Baxter Int | Esmolol formulation |
| ATE533509T1 (de) * | 2003-08-08 | 2011-12-15 | Ono Pharmaceutical Co | Herzverlangsamender arzneistoff mit beta-blockern mit kurzzeitwirkung als wirkstoff |
| US20080293814A1 (en) | 2007-05-22 | 2008-11-27 | Deepak Tiwari | Concentrate esmolol |
| CN101323580A (zh) | 2008-07-25 | 2008-12-17 | 河北科技大学 | 手性芳氧丙醇胺类化合物及其盐的合成方法 |
| CN101881755B (zh) | 2009-05-04 | 2013-05-29 | 南京海辰药业有限公司 | 通过高效液相色谱法检测盐酸艾司洛尔光学异构体的方法 |
| CN101891636A (zh) | 2009-05-21 | 2010-11-24 | 南京海辰药业有限公司 | 制备盐酸艾司洛尔光学异构体的新方法 |
| CN102106846A (zh) | 2009-12-23 | 2011-06-29 | 南京海辰药业有限公司 | 左旋盐酸艾司洛尔药物组合物及其制备方法 |
| AU2012211309B2 (en) | 2011-01-27 | 2014-10-09 | Baxter Healthcare Sa | Use of (S) - esmolol for controlling venous irritation associated with the treatment of a cardiac disorder |
-
2012
- 2012-01-26 AU AU2012211318A patent/AU2012211318C1/en not_active Ceased
- 2012-01-26 CN CN2012800065096A patent/CN103338763A/zh active Pending
- 2012-01-26 EP EP12702941.1A patent/EP2667867B1/en not_active Not-in-force
- 2012-01-26 CA CA2825311A patent/CA2825311A1/en not_active Abandoned
- 2012-01-26 BR BR112013016701A patent/BR112013016701A2/pt not_active IP Right Cessation
- 2012-01-26 MX MX2013008713A patent/MX2013008713A/es active IP Right Grant
- 2012-01-26 US US13/359,065 patent/US8686036B2/en active Active
- 2012-01-26 WO PCT/US2012/022696 patent/WO2012103314A1/en not_active Ceased
- 2012-01-26 KR KR1020137018030A patent/KR20140034729A/ko not_active Withdrawn
- 2012-01-26 JP JP2013551327A patent/JP2014505074A/ja not_active Withdrawn
-
2013
- 2013-11-08 US US14/075,857 patent/US9084763B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11759506B2 (en) | AADC polynucleotides for the treatment of Parkinson's disease | |
| US12319929B2 (en) | Compositions and methods for the treatment of Parkinson's disease | |
| JP6837486B2 (ja) | 加齢に関連する認知障害及び神経炎症を予防及び／又は治療する方法 | |
| JP2019524897A5 (enExample) | ||
| CN103179978A (zh) | Ave0010用于制造供治疗2型糖尿病用的药物的用途 | |
| JP2016516016A5 (enExample) | ||
| JP2011507857A5 (enExample) | ||
| CN1711101A (zh) | 孤独症及相似障碍的治疗 | |
| TW200831078A (en) | Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats | |
| JP2017506257A5 (enExample) | ||
| WO2021007382A1 (en) | Compositions and methods for the treatment of parkinson's disease | |
| JP2014511365A5 (enExample) | ||
| Hadaczek et al. | Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain | |
| Singh et al. | Intravenous dexmedetomidine vs. lignocaine in attenuating the hemodynamic responses during laryngoscopy and endotracheal intubation: a randomized double blind study | |
| JP2014505074A5 (enExample) | ||
| Rylkova et al. | Effects of NPY and the specific Y1 receptor agonist [D-His26]-NPY on the deficit in brain reward function and somatic signs associated with nicotine withdrawal in rats | |
| Tendulkar et al. | Prospective Comparison of Pressor and Airway Responses to IV Esmolol and IV Dexmedetomidine during Emergence from General Anaesthesia and Extubation. | |
| Xiao et al. | Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multicenter, randomized, double-blind, placebo-controlled study | |
| JP2012502105A5 (enExample) | ||
| US20230210942A1 (en) | Methods and compositions for modulating endothelial cell dysfunction | |
| WO2016001682A1 (en) | Treatment of hypertransaminasemia | |
| Farag | Dexmedetomidine in the neurointensive care unit | |
| Banerjee et al. | Comparative study between fentanyl and dexmedetomidine as adjuvant to ropivacaine in supraclavicular brachial plexus block: A prospective and randomized study | |
| JP2020143037A (ja) | 糖尿病合併心不全の治療用医薬組成物 | |
| Chunxian et al. | Clinical characteristics of neurogenic hypertension with facial nerve and trigeminal nerve compression and efficacy of microvascular decompression |